Difference between revisions of "Ovarian cancer"
Line 1,091: | Line 1,091: | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Ovarian_cancer#Gemcitabine_.28Gemzar.29|Gemcitabine]] | |[[Ovarian_cancer#Gemcitabine_.28Gemzar.29|Gemcitabine]] | ||
+ | |style="background-color:#eeee00"|Seems not superior | ||
+ | |- | ||
+ | |[http://www.ejcancer.com/article/S0959-8049(16)32425-X/fulltext Marth et al. 2016 (ENGOT-ov-6/TRINOVA-2)] | ||
+ | |style="background-color:#00CD00"|Phase III | ||
+ | |PLD & Trebananib | ||
|style="background-color:#eeee00"|Seems not superior | |style="background-color:#eeee00"|Seems not superior | ||
|- | |- | ||
Line 1,108: | Line 1,113: | ||
## '''PRO analysis:''' Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. [http://jco.ascopubs.org/content/32/13/1309.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687829 PubMed] | ## '''PRO analysis:''' Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. [http://jco.ascopubs.org/content/32/13/1309.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687829 PubMed] | ||
## '''Subgroup analysis:''' Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)31562-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27871723 PubMed] | ## '''Subgroup analysis:''' Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. [http://www.gynecologiconcology-online.net/article/S0090-8258(16)31562-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27871723 PubMed] | ||
+ | # Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017 Jan;70:111-121. Epub 2016 Dec 1. [http://www.ejcancer.com/article/S0959-8049(16)32425-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27914241 PubMed] | ||
# Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017 Feb 14;116(4):455-463. Epub 2017 Jan 24. [https://www.nature.com/bjc/journal/v116/n4/full/bjc2016435a.html link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28118323 PubMed] | # Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017 Feb 14;116(4):455-463. Epub 2017 Jan 24. [https://www.nature.com/bjc/journal/v116/n4/full/bjc2016435a.html link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28118323 PubMed] | ||
Revision as of 02:49, 16 August 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
51 regimens on this page
98 variants on this page
|
Guidelines
ESMO
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
- Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
NCCN
Primary chemotherapy for advanced/metastatic disease
Carboplatin & Docetaxel
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Vasey et al. 2004 | Phase III | Carboplatin & Paclitaxel | Seems not superior |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 1 hour once on day 1, given second
- Docetaxel (Taxotere) 75 mg/m2 IV over 1 hour once on day 1, given first
Supportive medications
- Dexamethasone (Decadron) 8 mg PO BID the day before, the day of, and day after Docetaxel (Taxotere)
- Ondansetron (Zofran) 8 mg or Granisetron (Kytril) 3 mg for antiemesis
21-day cycle for 6 cycles
References
- Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91. link to original article contains verified protocol PubMed
Carboplatin & Doxorubicin liposomal
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Pignata et al. 2006 (MITO-2) | Phase III | Carboplatin & Paclitaxel | Seems not superior |
Eligibility criteria for MITO-2 included: "a cytologic or histologic diagnosis of epithelial ovarian cancer (stage IC to IV according to International Federation of Gynecology and Obstetrics staging system).
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given first
- Doxorubicin liposomal (Doxil) 30 mg/m2 IV over 60 minutes once on day 1, given second
Supportive medications
- "No prophylactic use of G-CSF was recommended. Therapeutic and prophylactic use of G-CSF was allowed for febrile or afebrile grade 4 neutropenia."
21-day cycle for 3 to 6 cycles
All patients received 3 cycles of therapy. Patients with stable or responsive disease received an additional 3 cycles.
References
- Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer. 2006 Aug 1;6:202. contains verified protocol link to PMC article PubMed
- Update: Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35. Epub 2011 Aug 15. link to original article contains verified protocol PubMed
Carboplatin & Gemcitabine
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Gordon et al. 2011 | Phase III | Carboplatin & Paclitaxel | Seems not superior |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given second
- Gemcitabine (Gemzar) 1000 mg/m2 IV 30 minutes once per day on days 1 & 8, given first
21-day cycle for up to 6 cycles
Patients with complete response could optionally proceed to receive paclitaxel consolidation.
References
- Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. link to original article contains verified protocol PubMed
Carboplatin & Paclitaxel
back to top |
TC: Taxol (Paclitaxel), Carboplatin
Regimen #1, AUC 6/175
Study | Evidence | Comparator | Efficacy |
Gordon et al. 2011 | Phase III | Carboplatin & Gemcitabine | Seems not superior |
Burger et al. 2011 (GOG 218) | Phase III | Carboplatin, Paclitaxel, Bevacizumab initiation | Seems not superior |
Carboplatin, Paclitaxel, Bevacizumab throughout | Inferior PFS | ||
Perren et al. 2011 (ICON7) | Phase III | Carboplatin, Paclitaxel, Bevacizumab | Seems to have inferior PFS |
Pignata et al. 2014 (MITO-7) | Phase III | Weekly Carboplatin & Paclitaxel | Seems not superior |
Sugiyama et al. 2016 (JGOG3017/GCIG) | Phase III | Cisplatin & Irinotecan | Seems not superior |
Chemotherapy
- Carboplatin (Paraplatin) AUC 6 IV over 30 minutes once on day 1
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycle for up to 6 cycles
Patients with complete response in Gordon et al. 2011 could optionally proceed to receive paclitaxel consolidation.
Regimen #2, weekly carboplatin & paclitaxel
Study | Evidence | Comparator | Efficacy |
Pignata et al. 2014 (MITO-7) | Phase III | Carboplatin AUC 6 & Paclitaxel 175 | Seems not superior |
Chemotherapy
- Carboplatin (Paraplatin) AUC 2 IV once per week
- Paclitaxel (Taxol) 60 mg/m2 IV once per week
18-week course
Regimen #3, AUC 6/180
Study | Evidence | Comparator | Efficacy |
Katsumata et al. 2009 | Phase III | Carboplatin & dose-dense Paclitaxel | Seems to have inferior OS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 6 IV over 1 hour once on day 1
- Paclitaxel (Taxol) 180 mg/m2 IV over 3 hours once on day 1
Supportive medications
- "Standard premedication"
21-day cycle for 6 to 9 cycles, depending on response
Regimen #4, dose-dense paclitaxel
Study | Evidence | Comparator | Efficacy |
Katsumata et al. 2009 | Phase III | Conventional Carboplatin & Paclitaxel | Seems to have superior OS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 6 IV over 1 hour once on day 1
- Paclitaxel (Taxol) 80 mg/m2 IV over 1 hour once per day on days 1, 8, 15
Supportive medications
- "Standard premedication"
21-day cycle for 6 to 9 cycles, depending on response
Regimen #5, AUC 5/175
Study | Evidence | Comparator | Efficacy |
Vasey et al. 2004 | Phase III | Carboplatin & Docetaxel | Seems not superior |
Pignata et al. 2006 (MITO-2) | Phase III | Carboplatin & Pegylated liposomal doxorubicin | Seems not superior |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 1 hour once on day 1, given second
- MITO-2 gave carboplatin over 30 minutes
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
Supportive medications
- (per Vasey et al. 2004):
- Dexamethasone (Decadron) 20 mg PO given twice, at 12 and 6 hours prior to Paclitaxel (Taxol)
- Diphenhydramine (Benadryl) 50 mg IV or Chlorpheniramine (Chlor-Trimeton) 10 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- Ranitidine (Zantac) 50 mg IV or Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- Ondansetron (Zofran) 8 mg or Granisetron (Kytril) 3 mg for antiemesis
21-day cycle for 6 cycles
In MITO-2, all patients received 3 cycles of therapy. Patients with stable or responsive disease received an additional 3 cycles.
Regimen #6, AUC 7.5/175
Study | Evidence | Comparator | Efficacy |
Ozols et al. 2003 (GOG 158) | Phase III | Cisplatin & Paclitaxel | Seems to have non-inferior RFS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 7.5 IV once on day 1
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
Supportive medications
- Dexamethasone (Decadron) 20 mg PO given twice, at 12 and 6 hours prior to chemotherapy OR 20 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- Diphenhydramine (Benadryl) 50 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to Paclitaxel (Taxol)
21-day cycle for 6 cycles
References
- Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14. link to original article contains verified protocol PubMed
- Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91. link to original article contains verified protocol PubMed
- Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer. 2006 Aug 1;6:202. contains verified protocol link to PMC article PubMed
- Update: Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35. Epub 2011 Aug 15. link to original article contains verified protocol PubMed
- Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Oct 17;374(9698):1331-8. Epub 2009 Sep 18. link to original article contains verified protocol PubMed
- Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. link to original article contains verified protocol PubMed
- Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. link to original article contains verified protocol PubMed
- Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. link to original article contains verified protocol PubMed
- Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014 Apr;15(4):396-405. Epub 2014 Feb 28. link to original article PubMed
- Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. J Clin Oncol. 2016 Aug 20;34(24):2881-7. Epub 2016 Jul 11. link to original article contains protocol PubMed
Carboplatin, Paclitaxel, Bevacizumab
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Burger et al. 2011 (GOG 218) | Phase III | Carboplatin & Paclitaxel | Superior PFS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 6 IV over 30 minutes once on day 1
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
- Bevacizumab (Avastin) as follows:
- Cycle 1: none
- Cycles 2 to 6: 15 mg/kg IV once on day 1
21-day cycle for 6 cycles
Treatment followed by bevacizumab maintenance.
Regimen #2
Study | Evidence | Comparator | Efficacy |
Perren et al. 2011 (ICON7) | Phase III | Carboplatin & Paclitaxel | Seems to have superior PFS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 to 6 IV over 30 to 60 minutes once on day 1; the protocol linked from Perren et al. 2011 clarifies that the recommended dose was AUC 6, but that it could be adjusted "according to standard practice"
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
- Bevacizumab (Avastin) as follows:
- Cycle 1: not given if chemotherapy starts within 4 weeks of surgery. If greater than 4 weeks after surgery: 7.5 mg/kg IV once on day 1
- Cycles 2 to 6: 7.5 mg/kg IV once on day 1
21-day cycle for 6 cycles
Treatment followed by bevacizumab maintenance.
References
- Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. link to original article contains verified protocol PubMed
- Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. link to original article contains verified protocol PubMed
Cisplatin & Paclitaxel
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Ozols et al. 2003 (GOG 158) | Phase III | Carboplatin & Paclitaxel | Seems to have non-inferior RFS |
Armstrong et al. 2006 | Phase III | Intraperitoneal Cisplatin & Paclitaxel | Seems to have inferior OS |
Walker et al. 2006 | Phase III | Intraperitoneal Cisplatin & Paclitaxel | Not reported |
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV at an infusion rate of 1 mg/min once on day 1
- Paclitaxel (Taxol) 135 mg/m2 IV continuous infusion over 24 hours once on day 1
Supportive medications
- (details vary depending on reference):
- Dexamethasone (Decadron) 20 mg PO given twice, at 12 and 6 hours prior to chemotherapy OR 20 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- Diphenhydramine (Benadryl) 50 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- "Hydration and antiemetic agents" before Cisplatin (Platinol)
21-day cycle for 6 cycles
References
- Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14. link to original article contains verified protocol PubMed
- Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. link to original article contains verified protocol PubMed
- Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan;100(1):27-32. link to original article contains verified protocol PubMed
Maintenance/consolidation therapy
Altretamine (Hexalen)
back to top |
Regimen
Study | Evidence |
Alberts et al. 2004 | Phase II |
Chemotherapy
- Altretamine (Hexalen) 260 mg/m2 PO once per day on days 1 to 14
28-day cycles
References
- Alberts DS, Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer. 2004 Mar-Apr;14(2):224-8. PubMed
Bevacizumab (Avastin)
back to top |
Regimen
Study | Evidence |
Burger et al. 2011 (GOG 218) | Non-randomized portion of RCT |
Perren et al. 2011 (ICON7) | Non-randomized portion of RCT |
Treatment preceded by carboplatin, paclitaxel, bevacizumab.
Chemotherapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycle for 12 cycles (ICON7) or up to 16 cycles (GOG 218)
References
- Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. link to original article contains verified protocol PubMed
- Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. link to original article contains verified protocol PubMed
Paclitaxel (Taxol)
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Markman et al. 2003 (GOG 178) | Phase III | Paclitaxel for 12 cycles | Inferior PFS |
Chemotherapy
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
28-day cycle for 3 cycles
Regimen #2
Study | Evidence | Comparator | Efficacy |
Markman et al. 2003 (GOG 178) | Phase III | Paclitaxel for 3 cycles | Superior PFS |
Chemotherapy
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
28-day cycle for 12 cycles
Regimen #3
Study | Evidence |
Gordon et al. 2011 | Non-randomized portion of RCT |
Treatment preceded by carboplatin & gemcitabine x 6 versus carboplatin & paclitaxel x 6.
Chemotherapy
- Paclitaxel (Taxol) 135 mg/m2 IV once on day 1
28-day cycle for up to 12 cycles
Regimen #4
Study | Evidence |
Micha et al. 2005 | Phase II, <20 patients in this subgroup |
Treatment preceded by carboplatin, gemcitabine, paclitaxel x6.
Chemotherapy
- Paclitaxel (Taxol) 175 mg/m2 IV over 1 hour once on day 1
21-day cycle for 3 cycles
Regimen #5
Study | Evidence |
Micha et al. 2005 | Phase II, <20 patients in this subgroup |
Treatment preceded by carboplatin, gemcitabine, paclitaxel x6.
Chemotherapy
- Paclitaxel (Taxol) 175 mg/m2 IV over 1 hour once on day 1
21-day cycle for 12 cycles
References
- Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D; Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003 Jul 1;21(13):2460-5. link to original article contains verified protocol PubMed
- Update: Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009 Aug;114(2):195-8. Epub 2009 May 17. link to original article contains verified protocol link to PMC article PubMed
- Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Markman M. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol. 2005 Jan;96(1):132-5. link to original article contains verified protocol PubMed
- Retrospective: Abaid LN, Goldstein BH, Micha JP, Rettenmaier MA, Brown JV 3rd, Markman M. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology. 2010;78(5-6):389-93. Epub 2010 Aug 27. link to original article contains verified protocol PubMed
- Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. link to original article contains verified protocol PubMed
Pazopanib (Votrient)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Du Bois et al. 2014 (AGO-OVAR16) | Phase III | Placebo | Superior PFS |
Patients enrolled in AGO-OVAR16 had histologically confirmed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, were FIGO II to IV, and no evidence of progression after surgery and at least 5 cycles of platinum-taxane chemotherapy.
Chemotherapy
- Pazopanib (Votrient) 800 mg PO once per day
24-month course
References
- du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. Epub 2014 Sep 15. link to original article contains verified protocol PubMed
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Du Bois et al. 2014 (AGO-OVAR16) | Phase III | Pazopanib | Inferior PFS |
No treatment after initial platinum-taxane treatment. Used as a comparator arm and here for reference purposes only.
References
- du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. Epub 2014 Sep 15. link to original article contains verified protocol PubMed
Intraperitoneal therapy
Cisplatin & Paclitaxel
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Armstrong et al. 2006 | Phase III | Cisplatin & Paclitaxel | Seems to have superior OS |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 intraperitoneal rapid infusion once on day 2
- Paclitaxel (Taxol) 135 mg/m2 IV continuous infusion over 24 hours once on day 1, then 60 mg/m2 intraperitoneal rapid infusion once on day 8
Supportive medications
- "Standard premedication" for Paclitaxel (Taxol)
- "Hydration and antiemetic agents" before Cisplatin (Platinol)
- Intraperitoneal doses of cisplatin and paclitaxel are reconstituted in 2 liters of warm normal saline before infusion
21-day cycle for 6 cycles
Regimen #2
Study | Evidence | Comparator | Efficacy |
Walker et al. 2006 | Phase III | Cisplatin & Paclitaxel | Not reported |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 in 2 liters of normal saline, intraperitoneal rapid infusion once on day 2, with patient rolled onto 4 different positions every 15 minutes to evenly distribute cisplatin
- Paclitaxel (Taxol) 135 mg/m2 IV continuous infusion over 24 hours once on day 1, then 60 mg/m2 in 1 liter saline, intraperitoneal rapid infusion once on day 8
Supportive medications
- Additional 1 liter normal saline to be infused immediately after intraperitoneal Paclitaxel (Taxol)
- Supportive medications left to investigator discretion
21-day cycle for 6 cycles
References
- Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. link to original article contains verified protocol PubMed
- Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan;100(1):27-32. link to original article contains verified protocol PubMed
Relapsed or recurrent disease
Bevacizumab (Avastin)
back to top |
Regimen
Study | Evidence |
Burger et al. 2007 | Phase II |
Cannistra et al. 2007 | Phase II |
Chemotherapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Nov 20;25(33):5165-71. Erratum in: J Clin Oncol. 2014 Nov 10;32(32):3686. link to original article contains verified protocol PubMed
- Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20;25(33):5180-6. Erratum in: J Clin Oncol. 2008 Apr 1;26(10):1773. link to original article contains verified protocol PubMed
Carboplatin (Paraplatin)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Parmar et al. 2003 (ICON4/AGO-OVAR-2.2) | Phase III | Carboplatin & Paclitaxel Cisplatin & Paclitaxel |
Seems to have inferior OS |
Pfisterer et al. 2006 | Phase III | Carboplatin & Gemcitabine | Inferior PFS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV once on day 1
21-day cycle for 6 to 10 cycles
References
- Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. link to original article contains verified protocol PubMed
- Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11. link to original article contains verified protocol PubMed
Carboplatin & Docetaxel
back to top |
Regimen #1
Study | Evidence |
Strauss et al. 2007 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 30 to 60 minutes once on day 1, given second
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1, given first
Supportive medications
- Corticosteroids given twice, 12 hours and 30 minutes before Docetaxel (Taxotere)
- Prophylactic antiemetics with 5-HT3 antagonist
21-day cycle for 6 cycles
Regimen #2
Study | Evidence |
Kushner et al. 2007 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 2 IV over 30 minutes once per day on days 1, 8, 15, given second
- Docetaxel (Taxotere) 35 mg/m2 IV over 60 minutes once per day on days 1, 8, 15, given first
- Body surface area capped at 2 m2
Supportive medications
- Dexamethasone (Decadron) 4 mg PO the evening before, the morning of, and evening after Docetaxel (Taxotere)
- 5-HT3 antagonist before chemotherapy
- Phenothiazine or 5-HT3 antagonist as needed as an outpatient
- Diphenhydramine (Benadryl) 50 mg IV once immediately prior to Docetaxel (Taxotere)
28-day cycle for 6 cycles
References
- Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol. 2007 Mar;104(3):612-6. Epub 2006 Oct 27. link to original article contains verified protocol PubMed
- Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM; Wisconsin Oncology Network. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007 May;105(2):358-64. Epub 2007 Jan 29. link to original article contains verified protocol PubMed
Carboplatin & Doxorubicin liposomal
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Pujade-Lauraine et al. 2010 (CALYPSO) | Phase III | Carboplatin & Paclitaxel | Superior PFS |
CALYPSO: Caelyx (Pegylated liposomal doxorubicin) in Platinum Sensitive Ovarian patients
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV once on day 1
- Doxorubicin liposomal (Doxil) 30 mg/m2 IV once on day 1
Supportive medications
- "Antiemetics, including a serotonin antagonist and corticosteroid with 5-HT3 antagonist"
28-day cycle for 6 or more cycles, depending on response and toxicity
References
- Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9. Epub 2010 May 24. link to original article contains verified protocol PubMed
- Update: Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012 Aug 7;107(4):588-91. Epub 2012 Jul 26. link to original article contains verified protocol link to PMC article PubMed
Carboplatin & Gemcitabine
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Pfisterer et al. 2006 | Phase III | Carboplatin | Superior PFS |
Aghajanian et al. 2012 (OCEANS) | Phase III | Carboplatin, Gemcitabine, Bevacizumab | Inferior PFS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 4 IV once on day 1
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
21-day cycle for 6 to 10 cycles
References
- Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11. link to original article contains verified protocol PubMed
- Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23. link to original article contains verified protocol link to PMC article PubMed
- Update: Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015 Oct;139(1):10-6. Epub 2015 Aug 10. link to original article link to PMC article PubMed
Carboplatin, Gemcitabine, Bevacizumab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Aghajanian et al. 2012 (OCEANS) | Phase III | Carboplatin & Gemcitabine | Superior PFS |
Initial therapy
- Carboplatin (Paraplatin) AUC 4 IV once on day 1
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1, given first
21-day cycle for 6 to 10 cycles, based on response; after completing these cycles of carboplatin, gemcitabine, and bevacizumab, patients continue on bevacizumab maintenance until progression of disease or unacceptable toxicity
Bevacizumab maintenance
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles, given until progression of disease or unacceptable toxicity
References
- Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23. link to original article contains verified protocol link to PMC article PubMed
- Update: Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015 Oct;139(1):10-6. Epub 2015 Aug 10. link to original article link to PMC article PubMed
Carboplatin & Paclitaxel
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Parmar et al. 2003 (ICON4/AGO-OVAR-2.2) | Phase III | Carboplatin | Seems to have superior OS |
Pujade-Lauraine et al. 2010 (CALYPSO) | Phase III | Carboplatin & Pegylated liposomal doxorubicin | Inferior PFS |
Oza et al. 2014 | Randomized Phase II | Carboplatin, Paclitaxel, Olaparib | Inferior PFS |
Coleman et al. 2017 (NRG/GOG-0213) | Phase III | Carboplatin, Paclitaxel, Bevacizumab | Might have inferior OS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 to 6 IV once on day 1
- Paclitaxel (Taxol) 175 to 185 mg/m2 IV over 3 hours once on day 1
Supportive medications
- (varies depending on reference):
- Corticosteroids and prophylactic antiemetics with 5-HT3 antagonist
- Premedication (with steroids & antihistamines) prior to Paclitaxel (Taxol)
21-day cycles
References
- Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. link to original article contains verified protocol PubMed
- Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9. Epub 2010 May 24. link to original article contains verified protocol PubMed
- Update: Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012 Aug 7;107(4):588-91. Epub 2012 Jul 26. link to original article contains verified protocol link to PMC article PubMed
- Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6. link to original article PubMed
- Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-791. Epub 2017 Apr 21. link to original article contains protocol PubMed
Carboplatin, Paclitaxel, Olaparib
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Oza et al. 2014 | Randomized Phase II | Carboplatin & Paclitaxel | Superior PFS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 4 IV once on day 1
- Paclitaxel (Taxol) 175 mg/m2 IV once on day 1
- Olaparib (Lynparza) 200 mg PO BID on days 1 to 10
21-day cycles
Total number of cycles is not specified in the abstract, but at completion of this portion, patients proceed to olaparib maintenance.
References
- Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6. link to original article contains protocol PubMed
Cisplatin & Gemcitabine
back to top |
Regimen
Study | Evidence |
Rose et al. 2003 | Phase II |
Chemotherapy
- Cisplatin (Platinol) 30 mg/m2 IV once per day on days 1 & 8, given second
- Gemcitabine (Gemzar) 750 mg/m2 IV over 30 minutes once per day on days 1 & 8, given first
Supportive medications
- 5-HT3 antagonists
- Corticosteroids
- Prochlorperazine (Compazine)
- Magnesium supplementation with Cisplatin (Platinol)
21-day cycles
References
- Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol. 2003 Jan;88(1):17-21. link to original article contains verified protocol PubMed
Cisplatin & Paclitaxel
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Parmar et al. 2003 (ICON4/AGO-OVAR-2.2) | Phase III | Carboplatin | Seems to have superior OS |
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV once on day 1
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycles
References
- Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. link to original article contains verified protocol PubMed
Docetaxel (Taxotere)
back to top |
Regimen
Study | Evidence |
Rose et al. 2003 | Phase II |
Chemotherapy
- Docetaxel (Taxotere) 100 mg/m2 IV over 1 hour once on day 1
Supportive medications
- Dexamethasone (Decadron) 8 mg PO BID starting 24 hours before docetaxel, and continuing for 48 hours after docetaxel
- Diphenhydramine (Benadryl) 50 mg IV immediately prior to paclitaxel
- Antiemetics as needed
21-day cycles
References
- Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Feb;88(2):130-5. link to original article contains verified protocol PubMed
Doxorubicin liposomal (Doxil)
back to top |
Regimen #1, 40 mg/m2 dose
Study | Evidence | Comparator | Efficacy |
Ferrandina et al. 2008 | Phase III | Gemcitabine | Might have inferior ORR |
Pujade-Lauraine et al. 2014 (AURELIA) | Phase III | Pegylated liposomal doxorubicin & Bevacizumab | Inferior PFS |
Lindemann et al. 2017 (Ovaresist) | Phase III | Tamoxifen | Superior PFS |
Note: Ovaresist met its primary endpoint of superior HrQOL for the experimental (tamoxifen) arm but had inferior PFS (secondary endpoint) for the experimental arm, and this is the efficacy reported here.
Chemotherapy
- Doxorubicin liposomal (Doxil) 40 mg/m2 IV over 60 minutes once on day 1
Supportive medications
- Methylprednisolone (Solumedrol) 20 mg IV once 30 minutes prior to chemotherapy
28-day cycles
Regimen #2, 50 mg/m2 dose
Study | Evidence | Comparator | Efficacy |
Gordon et al. 2001 | Phase III | Topotecan | Might have superior PFS |
Mutch et al. 2007 | Phase III | Gemcitabine | Seems not superior |
Marth et al. 2016 (ENGOT-ov-6/TRINOVA-2) | Phase III | PLD & Trebananib | Seems not superior |
Chemotherapy
- Doxorubicin liposomal (Doxil) 50 mg/m2 IV over 60 minutes once on day 1
28-day cycles
References
- Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 Jul 15;19(14):3312-22. link to original article PubMed
- Update: Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004 Oct;95(1):1-8. link to original article contains verified protocol PubMed
- Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007 Jul 1;25(19):2811-8. link to original article contains verified protocol PubMed content property of HemOnc.org
- Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):890-6. link to original article contains verified protocol PubMed
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. link to original article contains verified protocol PubMed
- PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. link to original article link to PMC article PubMed
- Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article PubMed
- Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017 Jan;70:111-121. Epub 2016 Dec 1. link to original article contains protocol PubMed
- Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017 Feb 14;116(4):455-463. Epub 2017 Jan 24. link to original article contains protocol PubMed
Doxorubicin liposomal & Bevacizumab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Pujade-Lauraine et al. 2014 (AURELIA) | Phase III | Pegylated liposomal doxorubicin | Superior PFS |
Chemotherapy
- Doxorubicin liposomal (Doxil) 40 mg/m2 IV once on day 1
- Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
28-day cycles, given until progression of disease or unacceptable toxicity
References
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. link to original article contains verified protocol PubMed
- PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. link to original article link to PMC article PubMed
- Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article PubMed
Doxorubicin liposomal & Gemcitabine
back to top |
Regimen
Study | Evidence |
Ferrandina et al. 2005 | Phase II |
Chemotherapy
- Doxorubicin liposomal (Doxil) 30 mg/m2 IV over 60 minutes once on day 1, given first
- Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 minutes once per day on days 1 & 8
Supportive medications
- Metoclopramide (Reglan) before chemotherapy
21-day cycles
References
- Ferrandina G, Paris I, Ludovisi M, D'Agostino G, Testa A, Lorusso D, Zanghi M, Pisconti S, Pezzella G, Adamo V, Breda E, Scambia G. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol. 2005 Aug;98(2):267-73. link to original article contains verified protocol PubMed
Etoposide (Vepesid)
back to top |
Regimen
Study | Evidence |
Rose et al. 1998 | Phase II |
Chemotherapy
- Etoposide (Vepesid) 50 mg/m2 PO once per day on days 1 to 21
- Dosage for patients with previous pelvic radiation: 30 mg/m2 PO once per day on days 1 to 21; dose could be increased up to 50 mg/m2 depending on toxicity
28-day cycles
References
- Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998 Feb;16(2):405-10. link to original article contains verified protocol PubMed
Gemcitabine (Gemzar)
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Mutch et al. 2007 | Phase III | Pegylated liposomal doxorubicin | Seems not superior |
Kurzeder et al. 2016 (PENELOPE) | Phase III | Gemcitabine & Pertuzumab | Seems not superior |
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 to 60 minutes once per day on days 1 & 8
21-day cycles
Regimen #2
Study | Evidence | Comparator | Efficacy |
Ferrandina et al. 2008 | Phase III | Pegylated liposomal doxorubicin | Might have superior ORR |
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 minutes once per day on days 1, 8, 15
28-day cycles
References
- Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007 Jul 1;25(19):2811-8. link to original article contains verified protocol PubMed
- Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):890-6. link to original article contains verified protocol PubMed
- Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. link to original article contains verified protocol PubMed
Olaparib (Lynparza)
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Audeh et al. 2010 | Phase II | ||
Gelmon et al. 2011 | Phase II | ||
Ledermann et al. 2012 | Randomized Phase II | Placebo | Seems to have superior OS |
Kaufman et al. 2014 | Phase II |
Patients in Kaufman et al. 2014 were resistant to prior platinum-containing therapy.
Chemotherapy
- Olaparib (Lynparza) 400 mg PO BID
Continued until progression
Regimen #2
Study | Evidence | Comparator | Efficacy |
Moore et al. 2014 (SOLO1 & SOLO2) | Phase III | Placebo | TBD |
These are ongoing phase III maintenance trials. This is not the FDA-approved dose.
Chemotherapy
- Olaparib (Lynparza) 300 mg PO BID
References
- Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):245-51. Epub 2010 Jul 6. link to original article contains verified protocol PubMed
- Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011 Sep;12(9):852-61. Epub 2011 Aug 19. link to original article contains verified protocol PubMed
- Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. link to original article contains verified protocol PubMed
- Update: Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Sep 8. [Epub ahead of print] link to orignal article PubMed
- Abstract: Kathleen N. Moore, Paul DiSilvestro, Elizabeth S. Lowe, Sally Garnett, Eric Pujade-Lauraine. SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). 2014 ASCO Annual Meeting abstract TPS5616. link to abstract
- Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article contains verified protocol PubMed
Paclitaxel (Taxol)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Gynecologic Oncology Group et al. 2006 | Phase II | ||
Pujade-Lauraine et al. 2014 (AURELIA) | Phase III | Paclitaxel & Bevacizumab | Inferior PFS |
Monk et al. 2014 (TRINOVA-1) | Phase III | Paclitaxel & Trebananib | Inferior PFS |
Pignata et al. 2015 (MITO 11) | Randomized Phase II | Paclitaxel & Pazopanib | Inferior PFS |
Kurzeder et al. 2016 (PENELOPE) | Phase III | Paclitaxel & Pertuzumab | Seems not superior |
Lindemann et al. 2017 (Ovaresist) | Phase III | Tamoxifen | Superior PFS |
Note: PENELOPE reports giving paclitaxel on days 1, 8, 15 of a 21-day cycle, which is identical to the schedule below. Ovaresist met its primary endpoint of superior HrQOL for the experimental (tamoxifen) arm but had inferior PFS (secondary endpoint) for the experimental arm, and this is the efficacy reported here.
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 1 hour once per day on days 1, 8, 15, 22
Supportive medications
- Dexamethasone (Decadron) 10 mg PO/IV once 30 to 60 minutes prior to Paclitaxel (Taxol)
- Diphenhydramine (Benadryl) 25 to 50 mg IV once 30 to 60 minutes prior to Paclitaxel (Taxol)
- H2 blocker 30 to 60 minutes prior to Paclitaxel (Taxol)
28-day cycles
References
- Gynecologic Oncology Group, Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jun;101(3):436-40. Epub 2005 Dec 2. link to original article contains verified protocol PubMed
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. link to original article contains verified protocol PubMed
- PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. link to original article link to PMC article PubMed
- Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article PubMed
- Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul;15(8):799-808. Epub 2014 Jun 17. link to SD article PubMed
- Update: Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct;143(1):27-34. Epub 2016 Aug 18. link to SD article PubMed
- Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8. Epub 2015 Apr 14. link to original article contains protocol PubMed
- Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. link to original article contains verified protocol PubMed
- Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017 Feb 14;116(4):455-463. Epub 2017 Jan 24. link to original article contains protocol PubMed
Paclitaxel & Bevacizumab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Pujade-Lauraine et al. 2014 (AURELIA) | Phase III | Paclitaxel | Superior PFS |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15, 22
- Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
28-day cycles, given until progression of disease or unacceptable toxicity
References
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. link to original article contains verified protocol PubMed
- PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. link to original article link to PMC article PubMed
- Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article PubMed
Paclitaxel & Pazopanib
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Pignata et al. 2015 (MITO 11) | Randomized Phase II | Paclitaxel | Superior PFS |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV once per week
- Pazopanib (Votrient) 800 mg PO once per day
Given until progression of disease or unacceptable toxicity
References
- Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators.. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8. Epub 2015 Apr 14. link to original article contains protocol PubMed
Paclitaxel, nanoparticle albumin-bound (Abraxane)
back to top |
Regimen
Study | Evidence |
Teneriello et al. 2009 | Phase II |
Chemotherapy
- Paclitaxel, nanoparticle albumin-bound (Abraxane) 260 mg/m2 IV over 30 minutes once on day 1
21-day cycle for 6 to 8 cycles
References
- Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2009 Mar 20;27(9):1426-31. Epub 2009 Feb 17. link to original article contains verified protocol PubMed
Pazopanib (Votrient)
back to top |
Regimen
Study | Evidence |
Friedlander et al. 2010 | Phase II |
Chemotherapy
- Pazopanib (Votrient) 800 mg PO once per day
given until progression of disease or unacceptable toxicity
References
- Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010 Oct;119(1):32-7. Epub 2010 Jun 27. link to original article contains verified protocol PubMed
Pemetrexed (Alimta)
back to top |
Regimen
Study | Evidence |
Miller et al. 2009 | Phase II |
Chemotherapy
- Pemetrexed (Alimta) 900 mg/m2 IV over 10 minutes once on day 1
- Dosage for patients with previous radiation therapy: 700 mg/m2 IV over 10 minutes once on day 1
Supportive medications
- Folic acid 350 to 600 mcg PO once per day, starting 7 days before pemetrexed, to continue throughout therapy
- Cyanocobalamin (Vitamin B12) 1000 mcg IM once 7 days before pemetrexed (then 1000 mcg to be given once every 9 weeks thereafter)
- Dexamethasone (Decadron) 4 mg PO BID the day before, the day of, and day after Pemetrexed (Alimta)
- No NSAIDs (nonsteroidal anti-inflammatory drugs) for 2 days before or after pemetrexed
21-day cycles
References
- Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 1;27(16):2686-91. Epub 2009 Mar 30. link to original article contains verified protocol link to PMC article PubMed
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Ledermann et al. 2012 | Randomized Phase II | Olaparib | Seems to have inferior OS |
Moore et al. 2014 (SOLO1 & SOLO2) | Phase III | Olaparib | TBD |
Mirza et al. 2016 (ENGOT-OV16/NOVA) | Phase III | Niraparib | Inferior PFS |
No active antineoplastic treatment. Used as a comparator arm and here for reference purposes only.
References
- Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. link to original article contains verified protocol PubMed
- Abstract: Kathleen N. Moore, Paul DiSilvestro, Elizabeth S. Lowe, Sally Garnett, Eric Pujade-Lauraine. SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). 2014 ASCO Annual Meeting abstract TPS5616. link to abstract
- Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64. Epub 2016 Oct 7. link to original article PubMed
Rucaparib (Rubraca)
back to top |
Regimen
Study | Evidence |
Swisher et al. 2016 (ARIEL2 Part 1) | Phase II |
Chemotherapy
- Rucaparib (Rubraca) 600 mg PO BID
28-day cycles, given until progession of disease
References
- Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Nov 28. [Epub ahead of print] link to original article contains verified protocol PubMed
Topotecan (Hycamtin)
back to top |
Regimen #1, 5-day dosing
Study | Evidence | Comparator | Efficacy |
Sehouli et al. 2011 | Randomized Phase II | Weekly topotecan | Seems not superior |
Pujade-Lauraine et al. 2014 (AURELIA) | Phase III | Bevacizumab & Topotecan | Inferior PFS |
Kurzeder et al. 2016 (PENELOPE) | Phase III | Topotecan & Pertuzumab | Seems not superior |
Chemotherapy
- Topotecan (Hycamtin) 1.25 mg/m2 IV over 30 minutes once per day on days 1 to 5
21-day cycle for up to 12 months (Sehouli et al. 2011) or until progression of disease or unacceptable toxicity
Regimen #2, weekly dosing
Study | Evidence | Comparator | Efficacy |
Sehouli et al. 2011 | Randomized Phase II | 5-day topotecan | Seems not superior |
Pujade-Lauraine et al. 2014 (AURELIA) | Phase III | Bevacizumab & Topotecan | Inferior PFS |
Chemotherapy
- Topotecan (Hycamtin) 4 mg/m2 IV over 30 minutes once per day on days 1, 8, 15
28-day cycle for up to 12 months; in AURELIA, topotecan was given until progression of disease or unacceptable toxicity
Regimen #3
Study | Evidence | Comparator | Efficacy |
Gordon et al. 2001 | Phase III | Pegylated liposomal doxorubicin | Might have inferior PFS |
Chemotherapy
- Topotecan (Hycamtin) 1.5 mg/m2 IV over 30 minutes once per day on days 1 to 5
21-day cycles
References
- Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 Jul 15;19(14):3312-22. link to original article PubMed
- Update: Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004 Oct;95(1):1-8. link to original article contains verified protocol PubMed
- Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011 Jan 10;29(2):242-8. Epub 2010 Nov 29. link to original article contains verified protocol PubMed
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. link to original article contains verified protocol PubMed
- PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. link to original article link to PMC article PubMed
- Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article PubMed
- Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. link to original article contains verified protocol PubMed
Topotecan & Bevacizumab
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Pujade-Lauraine et al. 2014 (AURELIA) | Phase III | Topotecan | Superior PFS |
Chemotherapy
- Topotecan (Hycamtin) 4 mg/m2 IV once per day on days 1, 8, 15
- Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
28-day cycles, given until progression of disease or unacceptable toxicity
Regimen #2
Study | Evidence | Comparator | Efficacy |
Pujade-Lauraine et al. 2014 (AURELIA) | Phase III | Topotecan | Superior PFS |
Chemotherapy
- Topotecan (Hycamtin) 1.25 mg/m2 IV once per day on days 1 to 5
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles, given until progression of disease or unacceptable toxicity
References
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. link to original article contains verified protocol PubMed
- PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. link to original article link to PMC article PubMed
- Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article PubMed
back to top |
Regimen
Study | Evidence |
Rothenberg et al. 2004 | Phase II |
Chemotherapy
- Vinorelbine (Navelbine) 30 mg/m2 IV once per day on days 1 & 8
21-day cycles
References
- Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol. 2004 Dec;95(3):506-12. link to original article contains protocol PubMed
Maintenance after salvage therapy
Niraparib (Zejula)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Mirza et al. 2016 (NOVA) | Phase III | Placebo | Superior PFS |
Treatment preceded by platinum-containing chemotherapy; neither specific agents, combinations, nor doses are specified in the protocol.
Chemotherapy
- Niraparib (Zejula) 300 mg PO once per day
Continued until progression
References
- Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64. Epub 2016 Oct 7. link to original article contains verified protocol PubMed
Olaparib (Lynparza)
back to top |
Regimen
Study | Evidence |
Oza et al. 2014 | Non-randomized portion of RCT |
Treatment preceded by carboplatin, paclitaxel, olaparib.
Chemotherapy
- Olaparib (Lynparza) 400 mg PO BID
Continued until progression
References
- Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6. link to original article contains protocol PubMed
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Mirza et al. 2016 (NOVA) | Phase III | Niraparib | Inferior PFS |
No further treatment after platinum-containing chemotherapy; neither specific agents, combinations, nor doses are specified in the protocol.
References
- Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64. Epub 2016 Oct 7. link to original article contains verified protocol PubMed
Investigational agents
These are drugs under study with at least some promising results for this disease.